Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM)

The British Journal of Radiology
Parul ThakralVindhya Malasani

Abstract

Two radiosensitizing chemotherapeutic drugs, capecitabine (CAP) and temozolomide (TEM), are administered concurrently to enhance the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT). This study aims to assess the biodistribution and normal-organ and tumor radiation dosimetry for Lu-177 DOTATATE administered concurrently with CAP/TEM. 20 patients with non-resectable histologically confirmed gastroenteropancreatic neuroendocrine tumors with normal kidney function, a normal haematological profile and somatostatin receptor expression of the tumor lesions, as scintigraphically assessed by a Ga-68 DOTANOC scan, were included in two groups-case group (n = 10) and control group (n = 10). Patients included in case group were those who were advised concomitant CAPTEM therapy by the treating medical oncologist. Patients were administered CAP orally at a dose of 600mg m-2 bovine serum albumin twice a day for 14 days starting 9 days prior to PRRT and oral TEM as a single dose at a dose of 75 mg m-2 was given concurrently for the last 5 days commencing on the day of PRRT (days 9-14). In the control group, patients were treated with Lu-177 DOTATATE only. For PRRT, 6.4 GBq-7.6 GBq (173-207 mCi) of Lu-177 DOTATATE was admini...Continue Reading

References

May 15, 1991·International Journal of Radiation Oncology, Biology, Physics·B EmamiM Wesson
Oct 5, 2001·European Journal of Nuclear Medicine·D J KwekkeboomE P Krenning
Jan 10, 2003·Seminars in Radiation Oncology·Theodore S LawrenceCornelius McGinn
Mar 22, 2005·Cancer Biotherapy & Radiopharmaceuticals·Katarina SjögreenSven-Erik Strand
Jul 13, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Marta CremonesiGiampiero Tosi
Nov 18, 2006·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Tapas DasMeera Venkatesh
Jul 27, 2007·Cancer Biotherapy & Radiopharmaceuticals·Christiane WehrmannRichard P Baum
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dik J KwekkeboomEric P Krenning
Sep 4, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Mattias SandströmHans Lundqvist
Mar 6, 2012·European Journal of Nuclear Medicine and Molecular Imaging·B L R KamD J Kwekkeboom
Jul 11, 2012·Journal of Endocrinological Investigation·D FeroneF Minuto
Dec 12, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Mattias SandströmMark Lubberink
Jan 17, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ezgi IlanMark Lubberink
Oct 16, 2015·Clinical Nuclear Medicine·Marleen MelisRichard P Baum
Oct 17, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michael LjungbergStephan Walrand
May 11, 2016·European Journal of Nuclear Medicine and Molecular Imaging·Hendrik BergsmaDik J Kwekkeboom

❮ Previous
Next ❯

Citations

Sep 8, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Samuel AdantJean-Mathieu Beauregard
Jul 28, 2019·Current Treatment Options in Oncology·Mauro CivesFranco Silvestris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.